These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 7889289

  • 21. Glycoprotein IIb/IIIa receptor antagonist (2S)-2-[(2-Naphthyl-sulfonyl)amino]-3-[[2-([4-(4-piperidinyl)-2-[2-(4-piperidinyl)ethyl] butanoyl]amino)acetyl]amino]propanoic acid dihydrochloride (CRL42796), in combination with aspirin and/or enoxaparin, prevents coronary artery rethrombosis after successful thrombolytic treatment by recombinant tissue plasminogen activator.
    Hong TT, Driscoll EM, White AJ, Sherigill A, Giboulot TA, Lucchesi BR.
    J Pharmacol Exp Ther; 2003 Aug; 306(2):616-23. PubMed ID: 12734394
    [Abstract] [Full Text] [Related]

  • 22. Intravenous and endobronchial administration of G4120, a cyclic Arg-Gly-Asp-containing platelet GPIIb/IIIa receptor-blocking pentapeptide, enhances and sustains coronary arterial thrombolysis with rt-PA in a canine preparation.
    Yasuda T, Gold HK, Kohmura C, Guerrero L, Yaoita H, Fallon JT, Bunting S, Collen D.
    Arterioscler Thromb; 1993 May; 13(5):738-47. PubMed ID: 8485125
    [Abstract] [Full Text] [Related]

  • 23. Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries.
    Yao SK, Ober JC, Ferguson JJ, Anderson HV, Maraganore J, Buja LM, Willerson JT.
    Circulation; 1992 Dec; 86(6):1993-9. PubMed ID: 1451271
    [Abstract] [Full Text] [Related]

  • 24. Prevention of reocclusion following tissue type plasminogen activator-induced thrombolysis by the RGD-containing peptide, echistatin, in a canine model of coronary thrombosis.
    Holahan MA, Mellott MJ, Garsky VM, Shebuski RJ.
    Pharmacology; 1991 Dec; 42(6):340-8. PubMed ID: 1946598
    [Abstract] [Full Text] [Related]

  • 25. Blockade of the platelet P2Y12 receptor by AR-C69931MX sustains coronary artery recanalization and improves the myocardial tissue perfusion in a canine thrombosis model.
    Wang K, Zhou X, Zhou Z, Tarakji K, Carneiro M, Penn MS, Murray D, Klein A, Humphries RG, Turner J, Thomas JD, Topol EJ, Lincoff AM.
    Arterioscler Thromb Vasc Biol; 2003 Feb 01; 23(2):357-62. PubMed ID: 12588784
    [Abstract] [Full Text] [Related]

  • 26. Inhibition of coronary artery reocclusion after thrombolysis with an RGD-containing peptide with no significant effect on bleeding time.
    Tschopp JF, Driscoll EM, Mu DX, Black SC, Pierschbacher MD, Lucchesi BR.
    Coron Artery Dis; 1993 Sep 01; 4(9):809-17. PubMed ID: 8287215
    [Abstract] [Full Text] [Related]

  • 27. Enhancement of tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by combination with a humanized anti-glycoprotein IIb/IIIa monoclonal antibody, YM337, in a rhesus monkey model of coronary thrombosis.
    Kawasaki T, Sato K, Suzuki K, Sakai Y, Taniuchi Y, Kaku S, Yano S, Inagaki O, Tomioka K, Masuho Y, Yanagisawa I, Takenaka T.
    Thromb Haemost; 1998 Mar 01; 79(3):663-7. PubMed ID: 9531059
    [Abstract] [Full Text] [Related]

  • 28. Dissociation between the anti-aggregatory & anti-secretory effects of platelet integrin alpha IIb beta 3 (GPIIb/IIIa) antagonists, c7E3 and DMP728.
    Tsao PW, Forsythe MS, Mousa SA.
    Thromb Res; 1997 Oct 15; 88(2):137-46. PubMed ID: 9361367
    [Abstract] [Full Text] [Related]

  • 29. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
    Leadley RJ, Kasiewski CJ, Bostwick JS, Bentley R, McVey MJ, White FJ, Perrone MH, Dunwiddie CT.
    Thromb Haemost; 1997 Oct 15; 78(4):1278-85. PubMed ID: 9364998
    [Abstract] [Full Text] [Related]

  • 30. Effect of aspirin on platelet desaggregation induced by SR121566, a potent GP-IIb/IIIa antagonist.
    Savi P, Bernat A, Lalé A, Roque C, Zamboni G, Herbert JM.
    Platelets; 2000 Feb 15; 11(1):43-8. PubMed ID: 10938881
    [Abstract] [Full Text] [Related]

  • 31. Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis.
    Nicolini FA, Lee P, Rios G, Kottke-Marchant K, Topol EJ.
    Circulation; 1994 Apr 15; 89(4):1802-9. PubMed ID: 8149546
    [Abstract] [Full Text] [Related]

  • 32. Enhancement of tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)- ethylidene]-6,11-dihydrodibenz[b,e]oxepine-2-carboxylate monohydrate in a canine model of femoral thrombosis.
    Higo K, Karasawa A, Kubo K.
    Arzneimittelforschung; 1991 Dec 15; 41(12):1251-5. PubMed ID: 1815525
    [Abstract] [Full Text] [Related]

  • 33. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion.
    Haskel EJ, Prager NA, Sobel BE, Abendschein DR.
    Circulation; 1991 Mar 15; 83(3):1048-56. PubMed ID: 1900222
    [Abstract] [Full Text] [Related]

  • 34. Antiplatelet efficacy and specificity of DMP728, a novel platelet GPIIb/IIIa receptor antagonist.
    Mousa SA, Bozarth JM, Forsythe MS, Lorelli W, Thoolen MJ, Ramachandran N, Jackson S, De Grado W, Reilly TM.
    Cardiology; 1993 Mar 15; 83(5-6):374-82. PubMed ID: 7509257
    [Abstract] [Full Text] [Related]

  • 35. SC-49992, a mimetic of the peptide arginine-glycine-aspartic acid-phenylalanine that blocks platelet aggregation, enhances recombinant tissue plasminogen activator-induced thrombolysis and prevents reocclusion in a canine model of coronary artery thrombosis.
    Feigen LP, Nicholson NS, King LW, Campion JG, Tjoeng FS, Panzer-Knodle SG.
    J Pharmacol Exp Ther; 1993 Dec 15; 267(3):1191-7. PubMed ID: 8263779
    [Abstract] [Full Text] [Related]

  • 36. Animal models for arterial thrombolysis and prevention of reocclusion. Erythrocyte-rich versus platelet-rich thrombus.
    Gold HK, Yasuda T, Jang IK, Guerrero JL, Fallon JT, Leinbach RC, Collen D.
    Circulation; 1991 Jun 15; 83(6 Suppl):IV26-40. PubMed ID: 2040069
    [Abstract] [Full Text] [Related]

  • 37. Glycoprotein IIb/IIIa receptor antagonists inhibit the development of platelet procoagulant activity.
    Pedicord DL, Thomas BE, Mousa SA, Dicker IB.
    Thromb Res; 1998 Jun 15; 90(6):247-58. PubMed ID: 9700855
    [Abstract] [Full Text] [Related]

  • 38. Blockade of platelet membrane glycoprotein Ib receptors delays intracoronary thrombogenesis, enhances thrombolysis, and delays coronary artery reocclusion in dogs.
    Yao SK, Ober JC, Garfinkel LI, Hagay Y, Ezov N, Ferguson JJ, Anderson HV, Panet A, Gorecki M, Buja LM.
    Circulation; 1994 Jun 15; 89(6):2822-8. PubMed ID: 8205697
    [Abstract] [Full Text] [Related]

  • 39. Thrombolytic activity of a novel plasminogen activator, LY210825, compared with recombinant tissue-type plasminogen activator in a canine model of coronary artery thrombosis.
    Jackson CV, Crowe VG, Craft TJ, Sundboom JL, Grinnell BW, Bobbitt JL, Burck PJ, Quay JF, Smith GF.
    Circulation; 1990 Sep 15; 82(3):930-40. PubMed ID: 2118431
    [Abstract] [Full Text] [Related]

  • 40. Functional relevance of the expression of ligand-induced binding sites in the response to platelet GP IIb/IIIa antagonists in vivo.
    Murphy NP, Pratico D, Fitzgerald DJ.
    J Pharmacol Exp Ther; 1998 Aug 15; 286(2):945-51. PubMed ID: 9694954
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.